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a  b  s  t  r  a  c  t
Background/aim: Radiation oncology covers many different ﬁelds of knowledge and skills.
Indeed, this medical specialty links physics, biology, research, and formation as well as
surgical and clinical procedures and even rehabilitation and aesthetics. The current socio-
economic situation and professional competences affect the development and future or this
specialty. The aim of this article was to analyze and highlight the underlying pillars and foun-
dations of radiation oncology, indicating the steps implicated in the future developments or
competences of each.
Methods: This study has collected data from the literature and includes highlights from dis-
cussions carried out during the XVII Congress of the Spanish Society of Radiation Oncology
(SEOR) held in Vigo in June, 2013. Most of the aspects and domains of radiation oncology
were analyzed, achieving recommendations for the many skills and knowledge related to
physics, biology, research, and formation as well as surgical and clinical procedures and
even supportive care and management.
Results: Considering the data from the literature and the discussions of the XVII SEOR Meet-
ing,  the “waybill” for the forthcoming years has been described in this article including all
the  aspects related to the needs of radiation oncology.
Conclusions: Professional competences affect the development and future of this specialty.All  the types of radio-modulation are competences of radiation oncologists. On the other
hand, the pillars of Radiation Oncology are based on experience and research in every area
of  Radiation Oncology.
© 2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
article we  would like to describe our ‘waybill’ for radi-.  Backgroundhe term ‘waybill’ is literally a document used by a haulier
roviding detailed instructions related to the sending of a
erchandize shipment. Nowadays, this term is also used
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in order to uneventfully establish the steps required to
perform a great social, human or universal task. In thisV. Mun˜oz-Garzón), rovirosa@clinic.ub.es (Á. Rovirosa),
ation oncology considering our goals step by step and
taking into account the current global economic crisis
around the world. As in a ‘waybill’, some instructions are
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needed to accomplish these tasks and these are described
below.
1.1.  The  mission  of  radiation  oncology
Radiation oncology is a speciality involving medical, technical,
surgical and clinical praxis, research, teaching, and manage-
ment functions.
The clinical aspects involve the treatment of different
tumours by multidisciplinary teams in which radiation onco-
logists offer many  types of treatments also associated with the
use of radiomodulators. This implies the need for continuous
scientiﬁc updating and knowledge on how to manage all the
resources available.
2.  Developments  in  radiotherapy
equipment
Recent publication by Rajamanickam Baskar 2012 conﬁrms
radiotherapy curative power.1 Other important aspects related
to radiotherapy include organ preservation, palliation of pain
and, of course, an increase in survival.2 More  than 50% of
cancer patients receive radiotherapy, and there has been
a rise in the use of this therapeutic approach in benign
diseases.1,2
If the 20th century played an important role in the develop-
ment of radiation oncology,3 the progress in technology to date
in the 21st century has been impressive with regard to pre-
cision, veriﬁcation and quality assurance, allowing adaptive
treatments, dose escalation and a reduction in early and late
complications. The advances in morphological and functional
images have contributed to the improvements in each mod-
ern radiotherapy technique. Indeed, we  can expect the use
of hybrid positron emission tomography/magnetic resonance
(PET/MR) equipment for treatment planning in the forthcom-
ing future.4
Despite having initially been developed at the end of the
last century, the use of intensity-modulated radiotherapy
(IMRT), image-guided radiotherapy (IGRT), adaptive radiothe-
rapy and stereotactic body radiotherapy (SBRT) has not been
extensive until now. In 2012 Milano reported a 2- and 5-
year survival of 74 and 47%, respectively in oligometastatic
breast cancer patients treated by SBRT.5 Recent advances,
including continuous registry of movement  control, elastic
fusion, 4D treatment delivery, and different dose plan sum-
mation systems, have also been commercialized by different
companies.4,6
A report from the Department of Health Cancer Policy Team
in the UK in 2012 concluded that initiation of radiotherapy
within 31 days after achieving the diagnosis saved 2500 lives
per year.7 Recent data from Burnet et al. indicate that improve-
ment in survival could reach 25%.8 The Australian Cancer
Council estimated that over a period of 10 years (1996–2006),
almost 51,000 cancer patients eligible for radiotherapy did not
receive it, representing nearly 40,000 years of life lost to cancer
patients overall.9iotherapy 1 8 ( 2 0 1 3 ) 321–328
2.1.  Veriﬁcation  and  quality  control
Since the development of IGRT, better tumour and OAR def-
inition and treatment delivery control are assets which may
be incorporated into daily practice. IGRT is a veriﬁcation and
quality control measure. Despite the implementation of regu-
latory laws to control the clinical steps from the diagnosis to
treatment delivery in different European countries, including
Spain,10 technological advances develop more  quickly. Qual-
ity control using treatment protocols has shown an impact on
patient survival, however, there is a need for protocols adapted
to the new technological developments.11,12 Patients are more
controlled when included in protocols, clinical trials and guar-
anteed quality programmes.
3.  Radiomodulation:  physical,  chemical
and  biological
Radiomodulation in radiotherapy is the concurrent addition
of treatments: pharmacological, chemotherapeutic, biologi-
cal, or physical to be able to change the effects of radiation
to enhance the healing effect or protection of patients.
3.1.  Physical  radiomodulation
IMRT allows precise dose treatments protecting healthy tis-
sues, with an escalation in dose having an impact on the gain
in the therapeutic ratio with a reduction in acute and late tox-
icity in almost all tumour sites.13–20 One of the most frequently
studied and reported tumour sites that show important ben-
eﬁts with IMRT is nasopharynx carcinoma; the reduction
obtained in xerostomia results in an increase in quality of
life and local control with the most frequent type of relapse
being distant metastasis.21,22 Hypofractionation has provided
promising results in breast and prostate cancer, and its use
is being extended to treatments involving a reduction in the
overall treatment period with a subsequent impact on the
waiting lists of Radiation Oncology Departments.23,24 The use
of IGRT for treatment delivery is becoming increasingly neces-
sary. The association of IMRT, IGRT and 4D has demonstrated a
reduction in toxicity and an increase in overall survival in lung
cancer.25,26 Software allowing deformable fusion of geometry
for volume deﬁnition in treatment planning and for image-
guided treatment delivery provides better knowledge of the
dose administered to the tumours and organs at risk.27
Protons have also shown excellent results in uveal
melanoma. The results of prospective and retrospective series
comparing proton versus uveal plaques showed better results
with the former at 5 years (92–99% vs. 81–96%, respectively).27
In chordomas and chondrosarcomas, a higher radiotherapy
dose is allowed with a dose reduction in healthy tissue.28 Bene-
ﬁts have also been reported in children in need of craniospinal
irradiation considering the reduction of the dose in the exit
ﬁeld. Considering the cost of these machines and the number
of patients beneﬁting from them, one proton accelerator per
10 million inhabitants seems reasonable.
Brachytherapy developed after the discovery of radium has
greatly improved. Following the development of several soft-
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his technique currently allows geometric and dosimetric
adiation modulation. The results of fractionated HDR treat-
ent are reportedly similar to those of low-dose rate (LDR)
reatments and, moreover, allow a dose escalation with a
ain in therapeutic ratio. Although HDR brachytherapy is
ime consuming, new trends have evolved taking advantage
f the technological developments to reduce the number
f fractions. Indeed, some good results have been reported
n patients for prostate cancer treated with a single HDR
rachytherapy dose.29–34
.2.  Chemical  radiomodulation
he progressive developments in the combination of
hemotherapy and radiotherapy have led to this associa-
ion being the standard treatment in many  tumours such as
he head and neck, cervix, rectum and lung, among others.
hemotherapy modulates the action of radiotherapy increas-
ng the results of radiotherapy by different mechanisms,
esulting in an increase in local control and survival depending
n the tumour site. This association also plays an important
ole in organ preservation mainly in head and neck cancer.35–37
or example, the more  recently developed drugs such as temo-
olamide or capecitabin have shown advantages in brain and
apecitabin, mainly in breast and gastrointestinal carcino-
as, but even in lung cancers. One of the main advantages
f these molecules is their oral intake, thereby making their
dministration more  comfortable and reducing the ‘overload’
n the Oncology Department. Other drugs such as Zoledronic
cid have demonstrated activity in radiosensitization, increas-
ng apoptosis.38,39
.3.  Biological  radiomodulation
n this group of radiomodulators, monoclonal antibodies and
enetic therapy play an important role as response modiﬁers
uring radiotherapy; the administration of interleukin colony-
timulating growth factors, anti-angiogenesis drugs, vaccines
nd non-speciﬁc immunomodulators has extended in clini-
al practice and trials. The most useful in several squamous
umours is Cetuximab, mainly in head and neck cancer.40
Paediatric tumours, germinal tumours and squamous
umours seem to most beneﬁt from these treatments. DNA
epair inhibitors such as ABT-888 are under analysis in com-
ination with whole brain radiotherapy in patients with brain
etastases due to breast cancer (NCT00649207: Princess Mar-
aret CC Trial). BSI-201, a PARP inhibitor, is also under analysis
n triple-negative breast cancer associated with radiotherapy.
ut in a recent article in triple-negative breast cancer patients
ho  had received radiation therapy, local control improved
igniﬁcantly (recurrence with RT only 4% at 5y).41
.  Support  care
uring the course of radiotherapy patients need symptomatic
ontrol of acute side effects. Despite the appearance of
ew technology and the administration of more  sophisti-
ated radiotherapy treatments, patients still present pain,
ncreased skin damage with new targets such as cetuximab,therapy 1 8 ( 2 0 1 3 ) 321–328 323
mucositis, anaemia and vomiting caused by different
chemotherapy agents. Support care during radiotherapy is
becoming more  important and relief of these symptoms is part
of our tasks. Nursing protocols for controlling patient symp-
toms and nutritional support are of help in clinical practice
and, considering the concomitant use of radiomodulators,
medical protocols have also been developed by MASCC and
ESMO for vomiting.42
5.  Radiation  oncology  training
The future of Radiation Oncology should be considered by
trainees and their needs should be taken into account. The
forthcoming future should include a common part of train-
ing for medical and radiation oncologists considering that
these two medical specialities will work together increasingly
more  closely. With the vertiginous developments in medical
and radiation oncology, we can expect a strong compart-
mentalization by tumour sites, which will be considered as
subspecialities. Taking this into account, the number of people
working in oncology or in some tumour sites may be reduced.
As a result medical and radiation oncologists may need to
share knowledge and practices in order to be equal in many
aspects of clinical practice and thereby to avoid the loss of
human resources, mainly during the current world recession.
Radiation Oncology requires continuous formation fol-
lowing courses, meetings, work in cooperative groups and
research as part of the daily tasks in this specialty. The attain-
ment of the PhD has been simpliﬁed with the new “Reaal
Decreto 99/2011” in Spain and it is considered a part of the
credits obtained during formation.43 Training in speciﬁc ﬁelds
of radiation oncology such as brachytherapy and special tech-
niques also requires preparation and skill, which would entail
at least 5–6 years of training in the specialty.
6.  Research
Research is a slow continuous process that implies a mul-
tidirectional relationship between basic researchers, applied
physics, and clinical oncologists. Future developments in
research will arise from precision in radiation therapy tech-
niques, the combination of therapies with radiotherapy,
nanotechnology and individualized treatment based on the
prognosis of each patient. In the next years, knowledge on
genetics and tumour and healthy tissue response will deter-
mine the treatment of each patient.44
Funding in research is mainly based on the development
of new drugs and treatment strategies as demonstrated by
the large number of clinical trials published and ongoing.
Research is limited in radiation oncology by the cost of invest-
ment in high technology and also because of the number of
patients treated in a Radiation Oncology Department in clin-
ical practice. It is, therefore, difﬁcult to develop trials with
different fractionation schedules, IMRT results, brachytherapy
treatments and also comparing radiotherapy with surgery.45
As a result of these difﬁculties, there is a lack of relevant
clinical trials to justify the technology to the governmental
health care system in many  countries such as Spain.46 The
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Table 1 – Relationship between survival and distant
recurrence-free interval (DRFI).
Year of diagnosis DRFI < 3 years DRFI > 3 years P
1978–86 13 m 34 m <0.0001
1987–94 13 m 33 m <0.0001
1995–04 14 m 31 m <0.0001
2005–10 – 32 m –
P = 0.15 P = 0.57
Tevaarwerk, 2013; Ref. 53.m: months.
research opportunity for Radiation Oncology radiomodulation
is to work with new targets and new drugs as well as in
treatment individualization, ideally, associated with research
groups and consortia (West 2005).44
7.  Management
In the USA, 1500 people die every day due to cancer (285 in
Spain). Considering the magnitude of these numbers, the cost
of radiotherapy is only 6% of the overall investment against
cancer.47,48
Despite the large amounts of money spent on new
chemotherapy agents, the advances achieved have been pro-
portionally small.48,49 On the other hand, the relationship of
prescription habits and determined agents with cancer is a
known fact.50,51 Moreover, less is spent on prevention than on
investigation.48–51 Likewise, Bailar J. stated that the reduction
in mortality in cancer is mainly related to early diagnosis.48
Interleukins such as interferon made their debut in the
80s. Nonetheless, the most relevant development during this
decade was conservative treatment of breast cancer with con-
servative surgery plus radiotherapy, when indicated, showing
similar results to those achieved with mastectomy. Gene ther-
apy showed great advances in lymphoma in children and
testicular cancer.
The investment of billions of dollars during almost 100
years of research in cancer has been very optimistic consid-
ering the results obtained. Investment in cancer usually
considers the most frequent tumour sites. Survival of breast
cancer has improved over time, although only in those
patients with hormone receptor-negative disease.52,53 Table 1
shows that no general improvement in survival has been
observed over the last 30 years for patients who have devel-
oped distant disease recurrence after adjuvant chemotherapy
after adjusting for Distance Recurrence Free Interval (DRFI),53
regardless of the year of diagnosis and treatment.
Notwithstanding, investment in new agents continues
with their subsequent use leading to large expenditures
which are difﬁcult to calculate.54,55 Comparatively, radiothe-
rapy allows patient cure in about 50% of cancer patients when
administered alone or in association with surgery. Data pub-
lished by the UK Department of Health have shown that
radiotherapy represents 5% of the national investment in can-
cer and is considered the second treatment of choice in this
disease.56
Nowadays, high technology in radiotherapy could allow
similar results to those achieved with surgery at a lower cost,iotherapy 1 8 ( 2 0 1 3 ) 321–328
resulting in a cost/beneﬁt relationship. As an example, for the
SBRT technique in lung caner, Table 2 shows different treat-
ment options and their cost per year of life lived (quality of life
and age were not considered: crude cost). The results show a
beneﬁt in results and in costs for SBRT. Moreover, it should
be remarked that in many  patients treated by SBRT, surgery is
contraindicated.57–62
One of the handicaps of the new technologies in Radia-
tion Oncology Departments is that they increase the work
time of radiation oncologists by 5–10% while attempting
to maintain the waiting list within the RANZCR 2011
recommendations.63,64 Moreover, it has been estimated that
from 2010 to 2020 the number of patients requiring radio-
therapy will increase by 22%, with only an increase of 2% in
the number of professionals available. To alleviate this sit-
uation, it has been suggested that the number of residents
should be doubled.65 Indeed, the Allen Consulting Report for
the RANZCR 2012 recommended an increase of 8% in the num-
ber of radiation oncologists, 25% of technicians and 50% of
physicists for 2022.66
7.1.  Management  of  investment
The current data provided by experts and governmental
departments in Europe and the USA in relation to technolog-
ical needs in radiation oncology are useful, well done, and up
to date, with data on the number and type of treatment units
needed per country.
In Spain, there are 5 treatment unit machines per mil-
lion inhabitants (4/5 Linacs); 42% of the Radiation Oncology
Departments have IMRT, although only 17.6% use this tech-
nology and 40% of the departments have brachytherapy units.
However, the recommendations state that 6 Linacs should be
available per million inhabitants, thus, more  Linacs should be
acquired in Spain and Co60 Units and Linacs aged more  than
10–15 years should be eliminated.67,68 Nonetheless, the num-
ber of Linacs in Spain is still not enough and should, actually,
be 7 per million inhabitants, with IGRT and 2 brachyther-
apy units, considering that 2200 patients per million should
receive irradiation and the treatment should be started in less
than 31 days after diagnosis in 94% of the patients.69,70 The
number of Linacs available depends on the country, and in
the case of the Toronto area in Canada, 7.7 Linacs per million
inhabitants are considered to be needed with an even higher
number being considered in Australia considering the pop-
ulation dispersion.71 The beneﬁts of IMRT are clear in head
and neck and prostate cancer; it is considered that this tech-
nique should be used in 33% of all the treatments and in 24%
of inverse plannings. The time for treatment using IMRT  could
be faster than 3D conformational technique depending on the
unit.70–72,7,73 Table 3 shows the recommendations of the Royal
Australian and New Zealand College of Radiologists for the
needs of technology acquisition.
8.  Recommendations  for  SpainThe four main pillars of our speciality are healthcare tasks, for-
mation, experience and research, all of which also contribute
to cancer cure and the development of treatment strategies
reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) 321–328 325
Table 2 – Cost per year of life gained according to survival at 5 years in T1-2 lung cancer.57–62
Treatment Surgery SBRT RT No treatment
% Overall survival 44.2 45.2 7–15% 0
Years/100 patients 221 226 35–75 0
Cost 1 patient ($) 26,419 9551 6000 0
Cost 100 patients 264,1900 955,10
Cost of life-year gained ($) 11,954.3 4226.1
Table 3 – Recommendations of the Royal Australian and
New Zealand College of Radiologists for the needs of
technology acquisition (Aimee Lovett, 9-2-2012).
Necessary for some patients according to evidence-based results
Image-guided radiotherapy (IGRT)
(2D IGRT, 3D IGRT, MRI-guided IGRT)
Intensity modulated radiotherapy (IMRT)
(Linac based IMRT, VMAT, Tomotherapy)
Stereotactic radiation treatment
(Linac-based SRS, Gamma Knife, Tomotherapy)
Advanced imaging for treatment planning
(4DCT, MRI – CT Fusion, Fusion PET – CT)
Brachytherapy
(Electronic Brachytherapy, Permanent LDR Implant, Directional
LDR Permanent Brachytherapy)
Particle therapy
(3D Conformal proton therapy, Intensity-modulated proton
therapy, Heavy ion therapy)
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Fig. 1). Considering these main pillars some recommenda-
ions should be strongly considered in the management of
adiation oncology departments in Spain:
 Number of Linacs: 6.5 per million inhabitants.
 1 Radiation Oncologist/140 patients (add 1 doctor for every
special technique at full capacity and turn)
(approx. 19 Radiation Oncologists/1,000,000 inhabitants)
 1 nurse/400–500 patients
 2 TER/Linac and shift.
 1 Additional TER/brachytherapy and Simulator shifts.
 1 TER dosimetrist/400 patients
 1 physicist/300 patients
 1 clinical auxiliary/300 patients
 Brachytherapy units: 2 per million inhabitants.74,75
 Use of Radiomodulation (physical, chemical and biological).
HEALTHC ARE T ASKS
FORMA TION
EXPERIENCE  RESEARCH 
Fig. 1 – Feedback pillars of Radiation Oncology.0 600,000 0
 17,142,86–8500 Undetermined
- Inclusion in clinical practice of new technologies that have
shown good results (functional SRS, SBRT, IGRT, treatment of
benign diseases, extensive use of brachytherapy in different
tumour sites, etc.).
- Involvement in a plan of biological sample collection for
research (i.e. blood extraction in radiation oncology outpa-
tient departments).
- Work in multidisciplinary teams. Evidence-based guide-
lines are indispensable for work in different teams and for
patients in need of well controlled clinical trials.
- Waiting list for starting radiotherapy: for emergencies <24 h,
for urgent treatments in preferential cases <2 weeks and for
ordinary patients <31 days. A reduction of the waiting list to
<31 days is related to better survival.
- Radiation Oncologist Societies and administration author-
ities should work together to support the development of
new radiation oncology centres and investment in treat-
ment units, considering ﬁnancial commitments and the
economic situation of the country. Authorities, societies
and industry working together could achieve a system for
ﬁnancing changes and modernizing the scientiﬁc park at
the most opportune time.
- Scientiﬁc societies, professional colleges and authorities
should work together to facilitate the best formation in
radiation oncology and to establish future needs within
oncological plans. In addition, promotion of the formation
of radiation oncologists for research should be implemented
(1 researcher per million of inhabitants), and the recom-
mendations of societies for preclinical and clinical research
should be followed.
- Close cooperation should be adhered to between different
Radiation Oncology Centres, with the transfer of skills and
knowledge.
- Information and counselling should be provided on the ade-
quate use of radiotherapy to society and scientiﬁc entities.
- Simpliﬁed quality assurance programmes using a commer-
cial workﬂow (i.e. similar to network MosaiqR Elekta Co.,
AriaR Varian Co., etc.) with a no punitive system for reporting
incidences should be implemented. The control of pro-
ductivity using information technology software should be
included in all Radiotherapy Departments.
- Resource Management units should have updated lists of
costs that allow the survival of Radiation Oncology Depart-
ments adapted to the new technologies and staff needs.
- Appropriate use of IMRT  for use in those patients in whom
a diminution of secondary effects with impact on quality of
life is expected.
-  Healthcare communication programmes to increase the
perception of treatment quality.
- Participation of patients in committees related to informa-
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9.  Recommendations  for  investigation  in
Spain
It is essential to include basic, preclinical and clinical research
in our department as recommended by the SEOR 2010.76,77
Only two global, albeit laborious, recommendations:
- The inclusion of investigation in all the ﬁelds of patient care
improves healthcare in 2 aspects: the application of new,
very controlled concepts and the wait-and-see approach
during the processes.
- Revision of the results followed by publication.
10.  Conclusions
Radiation therapy should be considered essential in the con-
trol of cancer and should be part of national health planning
as a major health action.
The future depends on our marketing ability which, in turn,
depends on the publication of good results, and these depend
on better control of our patients and the efﬁcacy, effective-
ness and cost-effectiveness which will, in turn, beneﬁt our
departments.
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